- N Engl J Med 2022; 387:842-843
The development of a highly effective, oral, 6-month regimen for the treatment of multidrug-resistant tuberculosis, which previously took 18 to 24 months to cure, is one of the defining achievements of the tuberculosis research community in this century. The results of the Nix-TB study, which were published in the
- N Engl J Med 2022; 387:850-852
Investigators report findings from the use of an all-oral regimen of bedaquiline, pretomanid, and linezolid in patients in the United States with multidrug-resistant or extensively drug-resistant tuberculosis.
- N Engl J Med 2022; 387:810-823
A randomized trial of bedaquiline–pretomanid–linezolid for highly drug-resistant tuberculosis assessed the use of linezolid at 600 or 1200 mg for 9 or 26 weeks; the 600-mg dose for 26 weeks had a favorable profile.
- Original ArticleAug 27, 202210.1056/NEJMoa2208686
In comatose patients after out-of-hospital cardiac arrest, the incidence of death or severe disability was similar regardless of whether a restrictive or a liberal oxygenation strategy was used.
- Original ArticleAug 27, 202210.1056/NEJMoa2203094
In a randomized, placebo-controlled trial, patients with acute decompensated heart failure and volume overload who received intravenous acetazolamide plus a loop diuretic had a higher incidence of decongestion.
- N Engl J Med 2022; 387:738-747
A 48-year-old woman was evaluated for abdominal pain. CT showed numerous liver lesions and lung cysts and nodules; liver biopsy revealed an eosinophilic inflammatory infiltrate. A diagnosis was made.
- N Engl J Med 2022; 387:452-458
A 63-year-old woman presented with dyspnea and cough. She had been in her usual state of health until 2 days earlier, when myalgias and dyspnea with ambulation developed, followed by a cough productive of green sputum.
- N Engl J Med 2022; 387:261-269
A 34-year-old woman presented with hypercortisolism resulting from a metastatic pancreatic neuroendocrine tumor. Chest CT revealed patchy consolidation with cavitation and tree-in-bud opacities. Management decisions were made.
- N Engl J Med 2022; 386:2518-2519
…soon the sharpened features, and sunken eye, and fallen jaw, pale and cold, bearing the manifest impress of death’s signet, began to glow with returning animation…. During the British cholera epidemic of 1831, William O’Shaughnessy reported that the blood of victims “has lost a large portion of its water…a great...
- N Engl J Med 2022; 386:2459-2470
In this trial, a restrictive approach to intravenous fluid administration in critically ill patients with septic shock did not reduce deaths at 90 days.
- N Engl J Med 2022; 386:2387-2398
In this trial of intravenous vitamin C in adult patients with sepsis, those who received a vitamin C infusion had a higher risk of death or persistent organ dysfunction at 28 days than those who received placebo.
- N Engl J Med 2022; 386:2328-2329
The editors announce a new NEJM Group series on climate change and the increasingly urgent health and care delivery challenges we face. Articles will appear in the Journal, in NEJM Evidence, and in NEJM Catalyst Innovations in Care Delivery.
- N Engl J Med 2022; 386:2303-2314
Climate change and air pollution, largely caused by the burning of fossil fuels, pose serious harms to children’s health. Children from communities of color and low-income communities are disproportionately harmed.
- N Engl J Med 2022; 386:2255-2257
The U.S. Supreme Court’s reasoning in two Covid-19 cases threatens the power of Congress to legislate against risks in advance. Now, West Virginia v. EPA could have broad implications for protecting public health.
- N Engl J Med 2022; 386:2178-2187
In a placebo-controlled trial, treatment with the preferential phosphodiesterase 4B inhibitor BI 1015550 prevented a decrease in lung function over a 12-week period in patients with idiopathic pulmonary fibrosis.
- N Engl J Med 2022; 386:2235-2236
Fibrosis, defined as the pathologic accumulation of extracellular matrix, is the final outcome of several common chronic inflammatory, immune-mediated, and metabolic diseases and accounts for up to 45% of all deaths in the industrialized world.1 The approval of pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis...
- N Engl J Med 2022; 386:2221-2221
A 68-year-old man presented with a 2-month history of eye pain, redness, and blurry vision. He also had a 1-year history of dry cough, sinusitis, and unintentional weight loss. CT of the chest revealed lung nodules.